{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:36:55Z","timestamp":1793900215804,"version":"4.8.0"},"reference-count":133,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2019.00120","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T04:19:31Z","timestamp":1551932371000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["Bringing Cardiovascular Comorbidities in Acromegaly to an Update. How Should We Diagnose and Manage Them?"],"prefix":"10.3389","volume":"10","author":[{"given":"Ana M.","family":"Ramos-Lev\u00ed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Marazuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","volume":"89","author":"Holdaway","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B4","first-page":"1047","article-title":"Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension?","volume":"82","author":"L\u00f3pez-Velasco","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1530\/EJE-16-0562","article-title":"Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly","volume":"175","author":"Sardella","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B6","first-page":"S33","article-title":"Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly","volume":"155","author":"Lombardi","year":"1997","journal-title":"J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine Society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1530\/ERC-16-0106","article-title":"Mortality in acromegaly: a 20-year follow-up study","volume":"23","author":"Ritvonen","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s12020-015-0787-3","article-title":"Sleep apnea syndrome in acromegalic patients: can morphological evaluation guide us to optimize treatment?","volume":"51","author":"Ramos-Levi","year":"2016","journal-title":"Endocrine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11102-013-0506-0","article-title":"Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases","volume":"17","author":"Broder","year":"2014","journal-title":"Pituitary"},{"key":"B13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11102-015-0681-2","article-title":"SAGIT\u00ae: clinician-reported outcome instrument for managing acromegaly in clinical practice\u2013development and results from a pilot study","volume":"19","author":"Giustina","year":"2016","journal-title":"Pituitary"},{"key":"B14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s11102-017-0835-5","article-title":"Development of ACRODAT\u00ae, a new software medical device to assess disease activity in patients with acromegaly","volume":"20","author":"van der Lely","year":"2017","journal-title":"Pituitary"},{"key":"B15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1097\/HJH.0000000000000962","article-title":"Role of ambulatory blood pressure monitoring in patients with acromegaly","volume":"34","author":"Costenaro","year":"2016","journal-title":"J Hypertens"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APh\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of hih blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"B18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1023\/A:1020798430884","article-title":"Pathogenesis and prevalence of hypertension in acromegaly","volume":"4","author":"Bondanelli","year":"2001","journal-title":"Pituitary"},{"key":"B19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.1365-2265.2005.02370.x","article-title":"Hypertension in acromegaly and in the normal population: prevalence and determinants","volume":"63","author":"Vitale","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000438903","article-title":"Cardiovascular disease and sleep-disordered breathing in acromegaly","volume":"103","author":"Powlson","year":"2016","journal-title":"Neuroendocrinology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1210\/jcem.87.7.8643","article-title":"Early vascular alterations in acromegaly","volume":"87","author":"Brevetti","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/BF03345478","article-title":"Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features","volume":"22","author":"Terzolo","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"B23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/cen.12455","article-title":"The beneficial effect of acromegaly control on blood pressure values in normotensive patients","volume":"81","author":"Sardella","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1210\/jc.2016-1937","article-title":"The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes","volume":"101","author":"Portocarrero-Ortiz","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1161\/HYPERTENSIONAHA.113.03057","article-title":"Revisiting the relationship between blood pressure and insulin-like growth factor-1","volume":"63","author":"Schutte","year":"2014","journal-title":"Hypertension"},{"key":"B26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1530\/EJE-12-0084","article-title":"Predictors of morbidity and mortality in acromegaly: an Italian survey","volume":"167","author":"Arosio","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000082032","article-title":"Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease","volume":"62","author":"Mercado","year":"2004","journal-title":"Horm Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s12020-016-1191-3","article-title":"Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management","volume":"55","author":"Ramos-Levi Marazuela","year":"2017","journal-title":"Endocrine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/CRD.0000000000000215","article-title":"Acromegalic cardiomyopathy: and overview of risk factors, clinical manifestations and therapeutic options","volume":"26","author":"Goldberg","year":"2018","journal-title":"Cardiol Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1210\/jc.2014-2242","article-title":"No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy","volume":"99","author":"Winhofer","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1210\/en.2008-0143","article-title":"Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly","volume":"149","author":"Kamenicky","year":"2008","journal-title":"Endocrinology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1210\/jc.2011-0078","article-title":"Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity","volume":"96","author":"Kamenicky","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1161\/01.HYP.0000114604.52270.95","article-title":"Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries","volume":"43","author":"Rizzoni","year":"2004","journal-title":"Hypertension"},{"key":"B35","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/jc.2012-3072","article-title":"A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy","volume":"98","author":"Annamalai","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1152\/ajpendo.2001.281.6.E1326","article-title":"Effects of growth hormone on renal tubular handling of sodium in healthy humans","volume":"281","author":"Hansen","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1365-2265.2007.03047.x","article-title":"High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging","volume":"68","author":"Bogazzi","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1210\/jc.85.1.193","article-title":"Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1365-2265.2001.01218.x","article-title":"Growth hormone and heart","volume":"54","author":"Colao","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF00408662","article-title":"The effect of insulin-like growth factor-1 on adult rat cardiac contractility","author":"Freestone","year":"1996","journal-title":"Mol Cell Biochem"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.2214\/AJR.07.2031","article-title":"Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence","volume":"190","author":"Gouya","year":"2008","journal-title":"Am J Roentgenol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1046\/j.1365-2265.2003.01780.x","article-title":"Growth hormone, acromegaly, and heart failure: an intricate triangulation","volume":"59","author":"Sacc\u00e0","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1210\/jc.2004-0821","article-title":"Long-term outcome of patients with acromegaly and congestive heart failure","volume":"89","author":"Bihan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-4615-1579-1_5","article-title":"The heart in acromegaly","volume-title":"Growth Hormone and the Heart","author":"Losa","year":"2001"},{"key":"B45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12020-014-0327-6","article-title":"GH and the cardiovascular system: an update on a topic at heart","volume":"48","author":"Isgaard","year":"2015","journal-title":"Endocrine"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1210\/jc.2015-2675","article-title":"Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort","volume":"100","author":"dos Santos Silva","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/hrt.2010.205096","article-title":"Valvular heart disease: the next cardiac epidemic","volume":"97","author":"D' Arcy","year":"2010","journal-title":"Heart"},{"key":"B48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/heartjnl-2014-307020","article-title":"The modern epidemiology of heart valve disease","volume":"102","author":"Coffey","year":"2016","journal-title":"Heart"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1210\/jc.2002-021099","article-title":"High prevalence of cardiac valve disease in acromegaly: An observational, analytical, case-control study","volume":"88","author":"Colao","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1161\/hc4601.099489","article-title":"Activated myofibroblasts express catabolic enzymes and mediate matrix re- modeling in myxomatous heart valves","volume":"104","author":"Rabkin","year":"2001","journal-title":"Circulation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1210\/jc.2003-030849","article-title":"Increased prevalence of regurgitant valvular heart disease in acromegaly","volume":"89","author":"Pereira","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ghir.2006.02.002","article-title":"Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation","volume":"16","author":"van der Klaauw","year":"2006","journal-title":"Growth Horm IGF Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1365-2265.2011.04067.x","article-title":"Aortic root ectasia in patient with acromegaly: experience at a single center","volume":"75","author":"Casini","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1365-2265.2011.04131.x","article-title":"Aortic root ectasia in patients with acromegaly: an emerging complication","volume":"75","author":"Colao","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11102-016-0725-2","article-title":"Challenges in the diagnosis and management of acromegaly: a focus on comorbidities","volume":"19","author":"Abreu","year":"2016","journal-title":"Pituitary"},{"key":"B56","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/EJE-08-0138","article-title":"Increased aortic root diameters in patients with acromegaly","volume":"159","author":"van der Klaauw","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/oxfordjournals.eurheartj.a060047","article-title":"Arrhythmia profile in acromegaly","volume":"13","author":"Kahaly","year":"1992","journal-title":"Eur Heart J"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.ijcard.2012.11.109","article-title":"Cardiovascular involvement in patients affected by acromegaly: an appraisal","volume":"167","author":"Mosca","year":"2013","journal-title":"Int J Cardiol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s11102-016-0749-7","article-title":"Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-na\u00efve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment","volume":"19","author":"Warszawski","year":"2016","journal-title":"Pituitary"},{"key":"B60","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ijcard.2004.12.010","article-title":"Late potentials and ventricular arrhythmias in acromegaly","volume":"104","author":"Maffei","year":"2005","journal-title":"Int J Cardiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12020-012-9859-9","article-title":"Left ventricular synchronicity is impaired in patients with active acromegaly","volume":"44","author":"Klrl\u015f","year":"2013","journal-title":"Endocrine"},{"key":"B62","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1046\/j.1365-2265.2001.01256.x","article-title":"Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly","volume":"54","author":"Colao","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1742-1241.2008.01750.x","article-title":"Investigation of early atherosclerotic changes in acromegalic patients","volume":"64","author":"Kartal","year":"2010","journal-title":"Int J Clin Pract"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1210\/jc.2010-2225","article-title":"Changes in arterial stiffness but not carotid intimal thickness in acromegaly","volume":"96","author":"Paisley","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B65","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-07-0358","article-title":"AcroBel\u2013the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects","volume":"157","author":"Bex","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1210\/jc.2014-2670","article-title":"Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic","volume":"99","author":"Mercado","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B67","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/01.hjh.0000298988.87020.9a","article-title":"Hypertension and acromegaly in the elderly: French Registry Data","volume":"100","author":"Dupuy","year":"2007","journal-title":"Arch Mal Coeur Vaiss"},{"key":"B68","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1055\/s-0032-1323765","article-title":"Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly","volume":"45","author":"Anagnostis","year":"2013","journal-title":"Horm Metab Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1210\/jc.2005-2857","article-title":"Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography","volume":"91","author":"Cannavo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1210\/jc.2007-1213","article-title":"Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study","volume":"92","author":"Bogazzi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B71","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1530\/EJE-09-0945","article-title":"Acromegaly per se does not increase the risk for coronary artery disease","volume":"162","author":"Akutsu","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/08037050510034293","article-title":"Reduced nitric oxide levels in acromegaly: cardiovascular implications","volume":"14","author":"Ronconi","year":"2005","journal-title":"Blood Press"},{"key":"B73","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11102-016-0710-9","article-title":"Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors","volume":"19","author":"Yaron","year":"2016","journal-title":"Pituitary"},{"key":"B74","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1358\/mf.2009.31.7.1415895","article-title":"Increased plasma endothelin level as an endothelial marker of cardiovascular risk in patients with active acromegaly: a comparison with plasma homocysteine","volume":"31","author":"Kirilov","year":"2009","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1007\/BF03349164","article-title":"Diagnosis and treatment of acromegaly complications","volume":"26","author":"Giustina","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"B76","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s11102-012-0420-x","article-title":"A consensus on the diagnosis and treatment of acromegaly complications","volume":"16","author":"Melmed","year":"2013","journal-title":"Pituitary"},{"key":"B77","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0894-7317(89)80014-8","article-title":"Recommendations for quantification of the left ventricle by two-dimensional echocardiography. American Society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms","volume":"2","author":"Schiller","year":"1989","journal-title":"J Am Soc Echocardiogr"},{"key":"B78","first-page":"85","article-title":"Echocardiographic left ventricular hypertrophy: clinical characteristics. The Framingham Heart Study","volume":"114","author":"Levy","year":"1992","journal-title":"Clin Exp Hypertens"},{"key":"B79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1476-7120-8-19","article-title":"Current cardiac imaging techniques for detection of left ventricular mass","volume":"8","author":"Celebi","year":"2010","journal-title":"Cardiovasc Utrasound"},{"key":"B80","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0895-7061(94)00178-E","article-title":"Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient","volume":"8","author":"Bottini","year":"1995","journal-title":"Am J Hypertens"},{"key":"B81","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1046\/j.1365-2265.1998.00493.x","article-title":"Echocardiographic evidence for a direct effect of GH\/IGF-I hypersecretion on cardiac mass and function in young acromegalics","volume":"49","author":"Minniti","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1210\/jcem.87.7.8573","article-title":"Cardiovascular consequences of early-onset growth hormone excess","volume":"87","author":"Colao","year":"2002","journal-title":"J Clin Endoccrinol Metab"},{"key":"B83","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1365-2265.2006.02475.x","article-title":"Pulsed tissue Doppler identifies subclinical myocardial biventricular dysfunction in active acromegaly","volume":"64","author":"Galderisi","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1210\/jc.2003-030462","article-title":"Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly","volume":"88","author":"Spinelli","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B85","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1161\/01.CIR.90.2.779","article-title":"Association between QT interval and coronary heart disease in middle-aged and elderly men. The Zutphen Study","volume":"90","author":"Dekker","year":"1994","journal-title":"Circulation"},{"key":"B86","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12020-012-9828-3","article-title":"QT dispersion in patients with acromegaly","volume":"43","author":"Unubol","year":"2013","journal-title":"Endocrine"},{"key":"B87","doi-asserted-by":"publisher","first-page":"428","DOI":"10.20344\/amp.4966","article-title":"The evaluation of QT intervals during diagnosis and after follow-up in acromegaly patients","volume":"27","author":"Baser","year":"2014","journal-title":"Acta Med Port"},{"key":"B88","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11102-013-0482-4","article-title":"Assessment of cardiac autonomic functions by heart rate recovery, heart rate variability and QT dynamicity parameters in patients with acromegaly","volume":"17","author":"Dural","year":"2014","journal-title":"Pituitary"},{"key":"B89","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2265.2008.03292.x","article-title":"The GH-IGF-I axis and the cardiovascular system: clinical implications","volume":"69","author":"Colao","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B90","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/cen.12356","article-title":"Three noninvasive methods in the evaluation of subclinical cardiovascular disease in patients with acromegaly: epicardial fat thickness, aortic stiffness and serum cell adhesion molecules","volume":"80","author":"Topaloglu","year":"2014","journal-title":"Clin Endocrinol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.endinu.2018.01.008","article-title":"Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: expert consensus","volume":"65","author":"Bernabeu","year":"2018","journal-title":"Endocrinol Diabetes Nutr"},{"key":"B92","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(08)61622-0","article-title":"Obstructive sleep apnoea and its cardiovascular consequences","volume":"373","author":"Bradley","year":"2009","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S0028-3843(14)60103-1","article-title":"The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly","volume":"45","author":"Stelmachowska-Bana\u015b","year":"2011","journal-title":"Neurol Neurochir Pol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cen.12993","article-title":"Long-term treatment with pegvisomant for acromegaly: a 10-year experience","volume":"84","author":"Ramos-Lev\u00ed","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12020-016-1218-9","article-title":"Impact of acromegaly treatment on cardiovascular complications","volume":"55","author":"Ioachimescu","year":"2017","journal-title":"Endocrine"},{"key":"B96","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11102-007-0062-6","article-title":"The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly","volume":"11","author":"De Marinis","year":"2008","journal-title":"Pituitary"},{"key":"B97","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12020-016-0995-5","article-title":"Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly","volume":"55","author":"Auriemma","year":"2016","journal-title":"Endocrine"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP.17.S4.1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly\u22122011 update","volume":"17","author":"Katznelson","year":"2011","journal-title":"Endocr Pract"},{"key":"B99","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1046\/j.1365-2265.2003.01689.x","article-title":"Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide","volume":"58","author":"Colao","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B100","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/S1521-690X(09)70006-5","article-title":"Long-term acromegaly and associated cardiovascular complications: a case-based review","author":"Colao","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B101","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1046\/j.1365-2265.2001.01343.x","article-title":"Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients","volume":"55","author":"Minniti","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1210\/jcem.86.4.7376","article-title":"Is the acromegalia cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance","volume":"86","author":"Colao","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1210\/jc.85.9.3132","article-title":"Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1210\/jc.2006-2547","article-title":"Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis","volume":"92","author":"Maison","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B105","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11102-011-0318-z","article-title":"Improvement of cardiac parameters in patients with acromegaly treated with medical therapies","volume":"15","author":"Colao","year":"2012","journal-title":"Pituitary"},{"key":"B106","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/BF03344070","article-title":"Multicenter italian study group on lanreotide: improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study","volume":"25","author":"Lombardi","year":"2002","journal-title":"J Endocrinol Invest"},{"key":"B107","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1365-2265.2006.02639.x","article-title":"Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients","volume":"65","author":"Fatti","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1210\/jc.2007-2199","article-title":"No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B109","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1385\/ENDO:30:1:145","article-title":"Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature","volume":"30","author":"Erem","year":"2006","journal-title":"Endocrine"},{"key":"B110","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1067\/mhj.2002.122167","article-title":"Treatment of acromegaly improves myocardial abnormalities","volume":"143","author":"Vianna","year":"2002","journal-title":"Am Heart J"},{"key":"B111","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1677\/joe.1.06082","article-title":"Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts","volume":"187","author":"Smith","year":"2005","journal-title":"J Endocrinol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/j.1365-2265.2008.03441.x","article-title":"Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study","volume":"70","author":"Colao","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1210\/jc.2008-0299","article-title":"Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B114","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1210\/jc.2009-0941","article-title":"Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study","volume":"94","author":"Colao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B115","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000095535","article-title":"Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs","volume":"83","author":"Tolis","year":"2006","journal-title":"Neuroendocrinology"},{"key":"B116","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s11102-011-0361-9","article-title":"Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide","volume":"15","author":"Couture","year":"2012","journal-title":"Pituitary"},{"key":"B117","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1046\/j.1365-2265.2003.01876.x","article-title":"Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment","volume":"59","author":"Baldelli","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B118","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide C2402 Study Group. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide C2305 study group. pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B120","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-months of treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance","volume":"154","author":"Colao","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1210\/jc.2009-2570","article-title":"Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control","volume":"95","author":"Berg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B122","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/bs.pmbts.2015.10.016","article-title":"Genetic predictors of response to different medical therapies in acromegaly","volume":"138","author":"Ramos-Lev\u00ed","year":"2016","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B123","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1210\/jc.2006-1587","article-title":"Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance","volume":"92","author":"Pivonello","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B124","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/BF03346667","article-title":"The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues","volume":"33","author":"De Martino","year":"2010","journal-title":"J Endocrinol Invest"},{"key":"B125","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1530\/EJE-15-0500","article-title":"Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study","volume":"173","author":"Kuhn","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1001\/jama.1980.03310160041024","article-title":"Bromocriptine for an acromegalic patient. Improvement in cardiac function and carpal tunnel syndrome","volume":"244","author":"Luboshitzky","year":"1980","journal-title":"JAMA"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B128","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12020-014-0206-1","article-title":"Cabergoline treatment in acromegaly: pros","volume":"46","author":"Marazuela","year":"2014","journal-title":"Endocrine"},{"key":"B129","doi-asserted-by":"publisher","first-page":"E1714","DOI":"10.1210\/jc.2012-1833","article-title":"No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly","volume":"97","author":"Maione","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B130","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s12020-014-0183-4","article-title":"Cabergoline treatment in acromegaly: cons","volume":"46","author":"Kasuki","year":"2014","journal-title":"Endocrine"},{"key":"B131","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1530\/acta.0.1080026","article-title":"Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation","volume":"100","author":"Baldwin","year":"1985","journal-title":"Acta Endocrinol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1210\/jc.2003-031584","article-title":"Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly","volume":"89","author":"Ayuk","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B133","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ecl.2014.10.009","article-title":"Efficacy and complications of pituitary irradiation","volume":"44","author":"Ntali","year":"2015","journal-title":"Endocrinol Metab Clin North Am"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00120\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T04:19:34Z","timestamp":1551932374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00120\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":133,"alternative-id":["10.3389\/fendo.2019.00120"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2019.00120","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"article-number":"120"}}